Under Dr. Laurie Glimcher’s leadership, Dana-Farber Cancer Institute is embarking on a transformative journey with the creation of a new, dedicated cancer hospital, promising a future of specialized care and improved patient experiences in oncology.

This historical analysis reveals the medical community’s involvement in advocating eugenic practices, emphasizing the need for modern physicians to understand and confront the lasting impact of these ideologies on healthcare and society.

This pivotal study demonstrates that the combination of enfortumab vedotin and pembrolizumab not only extends progression-free survival but also significantly improves overall survival rates in patients with untreated advanced urothelial carcinoma.

Explore the latest findings on vibecotamab’s potential in R/R AML treatment, revealing promising results with an optimized dosing regimen that mitigates cytokine response syndrome while improving patient outcomes.

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.

In an era where specialty drug costs soar, Alternative Funding Programs present a complex solution, balancing cost containment with patient access to essential medications. These programs, while offering potential savings, may also introduce treatment delays and increased financial burdens for patients.